Quick Facts

• Seasonal Allergic Rhinitis: May provide symptomatic relief for nasal symptoms associated with seasonal allergies.
• Perennial Allergic Rhinitis: Helps to manage nasal symptoms that occur year-round.
• Vasomotor Rhinitis: Used for the treatment of non-allergic symptoms, such as rhinorrhea and nasal congestion.

---

Allespray is an approved medication used to provide symptomatic relief in several therapeutic areas, primarily focused on the nose. The medication may assist individuals in the management of symptoms associated with seasonal allergic rhinitis, commonly referred to as hay fever. This includes supporting relief from sneezing, itchy nose, and excessive clear or watery nasal discharge.

Additionally, Allespray provides an option for individuals needing therapeutic support for perennial allergic rhinitis, which involves similar symptoms that persist throughout the year. The medication is also indicated for the treatment of symptoms related to vasomotor rhinitis (non-allergic rhinitis), such as nasal congestion and rhinorrhea.

Official Eligibility Rules for Allespray

Allespray (azelastine nasal spray) is regulated for use based on specific age groups, health conditions, and physiological status, as documented in official government regulatory information.

Eligibility Classification	Official Regulatory Status
Contraindication	Prohibited for patients with known hypersensitivity or allergy to azelastine hydrochloride or any component of the formulation.
Pediatric Use	Approved for seasonal allergic rhinitis in children ge 5 years (or ge 6 years depending on formulation). Use is not established or not recommended in children younger than the minimum approved age.
Adolescent & Adult Use	Approved for seasonal and perennial allergic rhinitis in patients ge 12 years. Approved for vasomotor rhinitis in patients ge 12 years.
Pregnancy	Conditional Use (e.g., if benefit justifies risk to the fetus). There are no adequate and well-controlled studies in pregnant women.
Lactation	Caution is recommended as it is unknown if the medicine is excreted into human milk and whether it affects the nursing infant.
Organ Impairment	No specific data are available for patients with significant hepatic or renal impairment, requiring cautious consideration.

The regulatory eligibility structure strictly defines who can use the medicine based on safety data and established efficacy in specific populations. Use is restricted or not recommended where data is insufficient, such as in infants and young children below the approved age thresholds, or when a potential risk is documented for physiological states like pregnancy.

Allespray (azelastine hydrochloride) has specific interactions that can affect its safety profile, primarily related to its potential for causing drowsiness.

Interactions Causing Increased Drowsiness

• Central Nervous System (CNS) Depressants: Concurrent use of Allespray with alcohol or other medicines that slow the central nervous system (CNS depressants) should be avoided. Combining these substances can lead to additional reductions in alertness, increased drowsiness, and further impairment of mental and motor performance.

Pharmacokinetic Interactions

• Cimetidine: When cimetidine (a medicine sometimes used to reduce stomach acid) was taken orally with azelastine, it resulted in a significant increase in the amount of azelastine absorbed into the body. This increase was approximately 65% of the average maximum concentration of azelastine, likely due to cimetidine's ability to interfere with drug metabolism in the liver. This effect highlights the need for caution if these medicines are used together.
• Other Agents: Studies involving oral azelastine with erythromycin or ketoconazole did not show any clinically significant changes in azelastine's concentration or heart rhythm, suggesting these specific medicines do not pose a major interaction risk through this pathway.

Patients should inform their healthcare provider about all prescription drugs, over-the-counter medicines, vitamins, and herbal products they are using to manage any potential interactions appropriately.

Modulating Key Receptor Systems and Signaling

Allespray initiates its pharmacodynamic action by operating as a highly selective modulator within specific receptor systems expressed on cell surfaces. The mechanism involves an interaction at the primary molecular target that modifies the activity which affects the flow of excessive or dysregulated signaling. This action is aligned with domains that require precise receptor-mediated pathway adjustment to influence core regulatory systems.

Interfering with Downstream Molecular Cascades

Following receptor engagement, the drug's mechanism extends to modifying internal molecular cascades. Allespray is used to initiate or suppress specific signaling sequences that typically follow a heightened physiological response. This targeted interference modifies the transduction of the initial signal, influencing subsequent cellular events and physiological processes.

Altering the Activity of Physiological Processes

Allespray's action ultimately modifies the activity of overactive or underactive physiological processes within defined neural or humoral pathways. By altering activity patterns through its molecular mechanism, the compound alters pathway activity that is associated with overactive responses and modifies activity within the targeted biological systems.

How to Use Allespray — Administration Guidelines

Allespray, which contains the active ingredient azelastine, is strictly intended for intranasal use, meaning it is administered topically into the nasal passages. This medicine is formulated as a metered-dose nasal spray and is available in two strengths: 0.1% and 0.15% Azelastine HCl. The specific dosage and frequency depend on the strength and the intended use.

---

Standard Dosing and Schedule

The standard regimen for adults and adolescents (12 years and older) is typically two sprays per nostril, twice daily (BID), for both seasonal and perennial conditions. For certain indications, the 0.15% strength allows an alternative schedule of two sprays per nostril, once daily. Use should continue consistently throughout the period of exposure, as the product is suitable for long-term administration as directed.

---

Administration Requirements

Before the first use, or if the device has been unused for three or more days, the device must be primed by actuating the pump a specified number of times until a fine mist is observed. The medicine is administered while the head is held in an upright or slightly tilted position, and contact with the eyes must be strictly avoided.

---

Population-Specific Use

Specific dosing rules are established for the pediatric population: children aged 6 to 11 years are instructed to use one spray per nostril, twice daily. For older adults, no specific dose adjustment is generally required based on age or for those with renal or hepatic impairment.

Research Evidence / Overview of Studies for Allespray (Azelastine Nasal Spray)

The evidence base for Azelastine nasal spray (Allespray) consists primarily of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. This body of evidence describes how the medicine was evaluated for conditions characterized by fluctuating or episodic manifestations, focusing on patient-reported outcomes describing perceived discomfort.

---

Evidence for Seasonal Allergic Rhinitis (SAR)

Research exploring the use of Azelastine for Seasonal Allergic Rhinitis (SAR), commonly known as hay fever, was mainly conducted using short-term, placebo-controlled clinical trials. The research included adults and adolescents ( ge 12 years), and some trials also examined children ( ge 5 years). A key metric used was the Total Nasal Symptom Score (TNSS), which combines patient reports on the severity of four key symptoms: sneezing, a runny nose (rhinorrhea), nasal itching, and congestion. Findings describe patterns observed in studies comparing participants receiving Azelastine versus those receiving an inactive (placebo) nasal spray over periods typically lasting two to four weeks.

---

Evidence for Perennial Allergic Rhinitis (PAR)

For Perennial Allergic Rhinitis (PAR), clinical trials often included intermediate follow-up durations of three to six weeks. These studies evaluated adults and adolescents, as well as younger children ( ge 5 years), who experienced persistent symptoms. Researchers used the Reflective Total Nasal Symptom Score (rTNSS) to gather patient-reported outcomes describing perceived discomfort, including measures of sleep quality. In these contexts, research highlights changes measured during the study period for outcomes linked to inflammatory or irritative states.

---

Long-Term Studies and Follow-Up Data

The research conducted so far has focused primarily on exploring short-term symptom changes over defined time intervals. For SAR and VMR, the follow-up durations were often limited to two to four weeks, meaning there is limited information for long-term outcomes for continuous use over full seasons or many months. Comparative evidence is also lacking for Azelastine versus all active comparator treatments in rigorous, longer-term trials for PAR management. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. National Institute of Allergy and Infectious Diseases (NIAID) - Allergic Rhinitis
2. Azelastine nasal spray in the treatment of seasonal allergic rhinitis
3. Azelastine Nasal Spray 0.15% in the Treatment of Seasonal Allergic Rhinitis in Patients Aged 6 Years and Older

Official Storage and Disposal Requirements

Storage and disposal instructions for Allespray (Azelastine HCl nasal spray) are defined by regulatory labeling to ensure product stability and safety. This medication must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F).

Mandatory Storage Constraints:

• Do not freeze the bottle.
• Store the bottle in an upright position and keep it tightly closed.
• Keep the medicine out of the reach of children.

Product Longevity and Disposal: Do not use Allespray past the printed expiration date. The official discard rule requires the user to dispose of the bottle after a specified number of sprays (e.g., 200) have been used, even if some liquid remains. Follow local guidelines for the disposal of unused or expired pharmaceuticals.